Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review

Detalhes bibliográficos
Autor(a) principal: Torres, Sabrina
Data de Publicação: 2023
Outros Autores: da Silva, Ellison, Silva, Iran, Lima, João, Silva, Vitor
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412
Resumo: Brazil is one of the most diverse countries in the world when it comes to its plant species, with about 46,096 plants in more than nine different ecosystems, making it an indispensable area for research involving phytotherapy. Among the species that present therapeutic interests is Cannabis sativa L., which is a shrub from the Moraceae family that contains about 400 compounds, including more than 60 cannabinoids, the best known compounds of this group being tetrahydrocannabinol and cannabidiol. Thus, this study aims to investigate which phytochemical compounds are linked to the therapeutic properties of the species Cannabis sativa L. The active compounds, tetrahydrocannabinol, cannabidiol and pentacyclic triterpenes are responsible for various therapeutic activities, being mainly linked their mechanisms of action by the affinity to bind to G protein-coupled receptors, CB1 and CB2 present in the membranes of different human cells, having greater affinity for the CB1 receptor, being linked to psychoactive properties. It is believed that the effects of the action of cannabis compounds on the CB2 receptor may provide immunomodulatory effects, such as regulation of cytokine activity, as well as anti-inflammatory, antineoplastic, antimicrobial, analgesic, muscle relaxant, and antioxidant activities. Thus, the literature investigates that the phytochemical compounds, cannabidiol, tetrahydrocannabinol, and pentacyclic triterpenes are primarily responsible for the therapeutic properties of Cannabis sativa L.Keywords: Cannabis, phytochemical compounds, medicinal plants.
id RCAP_56528129b3379deafe1c9f707505fc86
oai_identifier_str oai:ojs.actafarmaceuticaportuguesa.com:article/412
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature reviewPropriedades terapêuticas dos compostos fitoquímicos da espécie Cannabis sativa L.: Uma revisão de literaturaBrazil is one of the most diverse countries in the world when it comes to its plant species, with about 46,096 plants in more than nine different ecosystems, making it an indispensable area for research involving phytotherapy. Among the species that present therapeutic interests is Cannabis sativa L., which is a shrub from the Moraceae family that contains about 400 compounds, including more than 60 cannabinoids, the best known compounds of this group being tetrahydrocannabinol and cannabidiol. Thus, this study aims to investigate which phytochemical compounds are linked to the therapeutic properties of the species Cannabis sativa L. The active compounds, tetrahydrocannabinol, cannabidiol and pentacyclic triterpenes are responsible for various therapeutic activities, being mainly linked their mechanisms of action by the affinity to bind to G protein-coupled receptors, CB1 and CB2 present in the membranes of different human cells, having greater affinity for the CB1 receptor, being linked to psychoactive properties. It is believed that the effects of the action of cannabis compounds on the CB2 receptor may provide immunomodulatory effects, such as regulation of cytokine activity, as well as anti-inflammatory, antineoplastic, antimicrobial, analgesic, muscle relaxant, and antioxidant activities. Thus, the literature investigates that the phytochemical compounds, cannabidiol, tetrahydrocannabinol, and pentacyclic triterpenes are primarily responsible for the therapeutic properties of Cannabis sativa L.Keywords: Cannabis, phytochemical compounds, medicinal plants.O Brasil é um dos países mais diversificados do mundo no que se refere às suas espécies vegetais, detém cerca de 46.096 plantas em mais de nove diferentes ecossistemas, sendo uma imprescindível área para pesquisas que envolvam a fitoterapia. Dentre as espécies de que apresentam interesses terapêuticos, está a Cannabis sativa L., que é um arbusto da família Moraceae que contém cerca de mais de 400 compostos, incluindo mais de 60 canabinóides, sendo os compostos mais conhecidos desse grupo o tetra-hidrocanabinol e o canabidiol. Assim, o presente estudo tem como objetivo investigar quais compostos fitoquímicos estão vinculados com as propriedades terapêuticas da espécie Cannabis sativa L. Os compostos ativos, tetra-hidrocanabinol, canabidiol e triterpenos pentacíclicos são responsáveis por diversas atividades terapêuticas, estando principalmente ligados seus mecanismos de ação pela afinidade em se ligar aos receptores acoplados à proteína G, CB1 e CB2 presentes nas membranas de diferentes células humanas, tendo maior afinidade para o receptor CB1, estando ligado às propriedades psicoativas. Acredita-se que os efeitos da ação dos compostos da Cannabis no receptor CB2 possam proporcionar efeitos imunomoduladores, como a regulação da atividade das citocinas, assim apresentado atividades anti-inflamatórias, antineoplásicas, antimicrobiana, analgésicas, relaxantes musculares e antioxidantes. Desse modo, a literatura investiga apresenta os compostos fitoquímicos, canabidiol, tetra-hidrocanabinol e triterpenos pentacíclicos são os principais responsáveis pelas propriedades terapêuticas da Cannabis sativa L.Palavras-chave: Cannabis, compostos fitoquímicos, plantas medicinais.Acta Farmacêutica Portuguesa2023-12-29info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412Acta Farmacêutica Portuguesa; v. 12 n. 2 (2023): Acta Farmacêutica Portuguesa 2023; 19-282182-3340reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412/310Torres, Sabrinada Silva, EllisonSilva, IranLima, JoãoSilva, Vitorinfo:eu-repo/semantics/openAccess2024-01-12T17:00:19Zoai:ojs.actafarmaceuticaportuguesa.com:article/412Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T01:30:17.882216Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
Propriedades terapêuticas dos compostos fitoquímicos da espécie Cannabis sativa L.: Uma revisão de literatura
title Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
spellingShingle Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
Torres, Sabrina
title_short Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
title_full Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
title_fullStr Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
title_full_unstemmed Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
title_sort Therapeutic properties of the phytochemical compounds of the species Cannabis sativa L.: A literature review
author Torres, Sabrina
author_facet Torres, Sabrina
da Silva, Ellison
Silva, Iran
Lima, João
Silva, Vitor
author_role author
author2 da Silva, Ellison
Silva, Iran
Lima, João
Silva, Vitor
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Torres, Sabrina
da Silva, Ellison
Silva, Iran
Lima, João
Silva, Vitor
description Brazil is one of the most diverse countries in the world when it comes to its plant species, with about 46,096 plants in more than nine different ecosystems, making it an indispensable area for research involving phytotherapy. Among the species that present therapeutic interests is Cannabis sativa L., which is a shrub from the Moraceae family that contains about 400 compounds, including more than 60 cannabinoids, the best known compounds of this group being tetrahydrocannabinol and cannabidiol. Thus, this study aims to investigate which phytochemical compounds are linked to the therapeutic properties of the species Cannabis sativa L. The active compounds, tetrahydrocannabinol, cannabidiol and pentacyclic triterpenes are responsible for various therapeutic activities, being mainly linked their mechanisms of action by the affinity to bind to G protein-coupled receptors, CB1 and CB2 present in the membranes of different human cells, having greater affinity for the CB1 receptor, being linked to psychoactive properties. It is believed that the effects of the action of cannabis compounds on the CB2 receptor may provide immunomodulatory effects, such as regulation of cytokine activity, as well as anti-inflammatory, antineoplastic, antimicrobial, analgesic, muscle relaxant, and antioxidant activities. Thus, the literature investigates that the phytochemical compounds, cannabidiol, tetrahydrocannabinol, and pentacyclic triterpenes are primarily responsible for the therapeutic properties of Cannabis sativa L.Keywords: Cannabis, phytochemical compounds, medicinal plants.
publishDate 2023
dc.date.none.fl_str_mv 2023-12-29
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412
url https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412
https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/412/310
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Acta Farmacêutica Portuguesa
publisher.none.fl_str_mv Acta Farmacêutica Portuguesa
dc.source.none.fl_str_mv Acta Farmacêutica Portuguesa; v. 12 n. 2 (2023): Acta Farmacêutica Portuguesa 2023; 19-28
2182-3340
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136784761749504

Registros relacionados